Powering clients to a future shaped by growth

Monoclonal Antibody Therapies Transforming the Global Biologics Market

Advances in recombinant deoxyribonucleic acid (DNA) technologies have facilitated large-scale manufacturing of biologics products such as human growth factors, monoclonal antibody therapies (mAbs), and fusion proteins. In addition, improvements in analytical technologies have enabled improved characterization of macromolecules, including proteins and nucleic acids. This allows for the screening and identification of novel biologics with complex structures and various therapeutic functions. As a result, a number of biologics, including Humira®, Keytruda®, Opdivo®, Enbrel®, Eylea®, Avastin®, Stelara® and Rituxan®, accounted for the largest sales revenues in 2019 (Source: Evaluate Pharma and Frost & Sullivan Analyses).

The global biologics market is expected to grow from $284.08 billion in 2019 to $419.66 billion in 2024, registering a CAGR of 8.1% (Figure 1). Coronavirus 2019 (Covid-19) is expected to drive down market revenues in the short term due to delays in product launches and a decline in sales revenue of drugs. However, the development of Covid-19 vaccines and therapeutic drugs targeting the virus will have a positive impact on the recovery of the global biologics market over next five years.

Download eBook